Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Recent Developments and HELIOS-B Trial Results The cornerstone of Alnylam’s recent success has been the positive results from the HELIOS-B trial for Amvuttra in ATTR-CM patients. The trial ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Recent Developments and HELIOS-B Trial Results The cornerstone of Alnylam’s recent success has been the positive results from the HELIOS-B trial for Amvuttra in ATTR-CM patients. The trial ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The FDA approval is based on a clinical trial involving 655 people with ATTR-CM. The results showed that Amvuttra reduced the risk of death and repeat heart-related events by 28% over 36 months.